Ampersand Capital Partners
Signal active
Investment Firm
Overview
Ampersand is a middle market private equity firm that focuses on healthcare and industrial sectors.
Highlights
Founded
1988
Industry
Financial Services
Employees
11-50
Investment
70
Lead Investment
32
Exits
33
Stages
Late Stage Venture, Early Stage Venture, Private Equity, Seed
Investor Type
Private Equity Firm
Location
United States, North America
Contact Information
Social
Profile Resume
Ampersand Capital Partners, established in 1988 and headquartered in United States, North America., specializes in Late Stage Venture, Early Stage Venture, Private Equity, Seed investments across Enterprise Software, Software, E-Commerce, Search Engine, Financial Services, Venture Capital, Finance, FinTech, Business Development, Education. The organization boasts a portfolio of 70 investments, with an average round size of $20.0M and 33 successful exits. Their recent investments include Endeca, Bessemer Venture Partners, Venrock, DN Capital, Lehman Holdings. The highest investment round they participated in was $38.0B. Among their most notable exits are Endeca and Bessemer Venture Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Ampersand Capital Partners has made 70 investments. Their most recent investment was on Nov 02, 2023, when Genezen raised $18.5M.
Ampersand Capital Partners has made 7 diversity investments. Their most recent diversity investment was on Jan 30, 2017, when Canopy Biosciences raised $2.0M.
investments
70
Diversity investments
7
Lead investments
32
Number of exits
33
Investments
70
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jun 27, 2023 | Vernal Biosciences | Biotechnology | 20.0M |
| Nov 02, 2023 | Genezen | Biotechnology | 18.5M |
| Nov 20, 2023 | ProtaGene | Biotechnology | null |
| Nov 28, 2023 | Julius Clinical | Health Care | null |
Exits
33
Funding Timeline
Funding rounds
70
Investors
0
Funds
4
Funding Rounds
70
Ampersand Capital Partners has raised 70 rounds. Their latest funding was raised on Nov 28, 2023 from a Private Equity Round - Julius Clinical round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jun 27, 2023 | Series A - Vernal Biosciences | - | 20.0M | - |
| Nov 02, 2023 | Venture Round - Genezen | - | 18.5M | - |
| Nov 20, 2023 | Private Equity Round - ProtaGene | - | 0 | - |
| Nov 28, 2023 | Private Equity Round - Julius Clinical | - | 0 | - |
Investors
1
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
| - | No | Venture Round - Ampersand Capital Partners | 18.8M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.